X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
indacaterol/glycopyrronium (33) 33
chronic obstructive pulmonary disease (28) 28
indacaterol (27) 27
index medicus (27) 27
respiratory system (23) 23
glycopyrronium (21) 21
obstructive pulmonary-disease (21) 21
tiotropium (19) 19
copd (18) 18
lung diseases, obstructive (18) 18
humans (17) 17
pulmonary disease, chronic obstructive - drug therapy (16) 16
double-blind (14) 14
female (13) 13
glycopyrrolate - administration & dosage (13) 13
male (13) 13
indans - administration & dosage (12) 12
quinolones - administration & dosage (12) 12
qva149 (12) 12
aged (11) 11
bronchodilator agents - administration & dosage (11) 11
treatment outcome (11) 11
diseases of the respiratory system (10) 10
middle aged (10) 10
muscarinic antagonists - administration & dosage (10) 10
adrenergic beta-2 receptor agonists - administration & dosage (9) 9
salmeterol-fluticasone (9) 9
adrenergic beta-2 receptor agonists - adverse effects (8) 8
drug therapy (8) 8
muscarinic antagonists - adverse effects (8) 8
original research (8) 8
parallel-group (8) 8
salmeterol/fluticasone (8) 8
administration, inhalation (7) 7
bronchodilator agents - adverse effects (7) 7
disease progression (7) 7
dyspnea (7) 7
fluticasone (7) 7
forced expiratory volume (7) 7
inhaled corticosteroids (7) 7
mortality (7) 7
pulmonary disease, chronic obstructive - diagnosis (7) 7
research (7) 7
clinical trials (6) 6
double-blind method (6) 6
drug combinations (6) 6
efficacy (6) 6
exacerbation (6) 6
exacerbations (6) 6
fluticasone-salmeterol drug combination - administration & dosage (6) 6
glycopyrrolate - adverse effects (6) 6
international journal of chronic obstructive pulmonary disease (6) 6
lung diseases (6) 6
lung function (6) 6
lung-function (6) 6
pharmacology & pharmacy (6) 6
safety (6) 6
salmeterol (6) 6
analysis (5) 5
care and treatment (5) 5
dosage and administration (5) 5
drug therapy, combination (5) 5
dual bronchodilation (5) 5
health status (5) 5
indans - adverse effects (5) 5
laba (5) 5
lung - drug effects (5) 5
lung - physiopathology (5) 5
obstructive lung disease (5) 5
patients (5) 5
prevention (5) 5
pulmonary disease, chronic obstructive - physiopathology (5) 5
quality of life (5) 5
quinolones - adverse effects (5) 5
respiratory tract diseases (5) 5
risk (5) 5
time factors (5) 5
adult (4) 4
bronchodilator agents (4) 4
clinical medicine (4) 4
comparative analysis (4) 4
cost-effective (4) 4
development and progression (4) 4
fixed-dose combination (4) 4
glycopyrrolate (4) 4
health aspects (4) 4
medical research (4) 4
medicine, general & internal (4) 4
respiratory function (4) 4
severity of illness index (4) 4
surveys and questionnaires (4) 4
triple therapy (4) 4
adrenal cortex hormones - administration & dosage (3) 3
adrenergic beta-2 receptor agonists - therapeutic use (3) 3
asian continental ancestry group (3) 3
bronchodilator agents - therapeutic use (3) 3
case report (3) 3
cid (3) 3
clinically important deterioration (3) 3
combination (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 6 - 10
We present the case of a 77-year-old man diagnosed with chronic obstructive pulmonary disease (COPD) stage D with emphysema phenotype and treated with triple... 
Case Report | Chronic obstructive pulmonary disease | GOLD stage | Ventilatory response to exercise | Indacaterol/ glycopyrronium | MILD | Indacaterol/glycopyrronium | DIAGNOSIS | MANAGEMENT | RESPIRATORY SYSTEM | CONSTRAINTS | EXERCISE | COPD | Tiotropium | Medical research | Lung diseases, Obstructive | Medicine, Experimental | Development and progression | Indacaterol | Fluticasone
Journal Article
American journal of respiratory and critical care medicine, ISSN 1535-4970, 2018, Volume 198, Issue 3, pp. 329 - 339
Journal Article
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2017, Volume 2018, Issue 2, p. CD012066
Journal Article
Advances in Therapy, ISSN 0741-238X, 3/2019, Volume 36, Issue 3, pp. 495 - 519
Maintenance bronchodilator therapy with long-acting β-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) is the cornerstone treatment for patients... 
Indacaterol/glycopyrronium | Rheumatology | Internal Medicine | Oncology | Olodaterol/tiotropium | Medicine & Public Health | Asia | Fixed-dose combination | Formoterol/aclidinium | Vilanterol/umeclidinium | Long-acting muscarinic antagonists | Long-acting β-agonists | Chronic obstructive pulmonary disease | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | Long-acting beta-agonists | PHARMACOLOGICAL CHARACTERIZATION | QVA149 INDACATEROL/GLYCOPYRRONIUM | OBSTRUCTIVE PULMONARY-DISEASE | ACLIDINIUM BROMIDE | 5 MU-G | ONCE-DAILY INDACATEROL | TWICE-DAILY SALMETEROL | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | CHINESE PATIENTS | Bronchodilator Agents - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Muscarinic Antagonists - adverse effects | Muscarinic Antagonists - therapeutic use | Benzyl Alcohols - therapeutic use | Indans - therapeutic use | Quinuclidines - therapeutic use | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Tiotropium Bromide - therapeutic use | Bronchodilator Agents - adverse effects | Formoterol Fumarate - therapeutic use | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Tropanes - therapeutic use | Benzoxazines - therapeutic use | Muscarinic Antagonists - administration & dosage | Asian Continental Ancestry Group | Chlorobenzenes - therapeutic use | Adrenergic beta-2 Receptor Agonists - administration & dosage | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | aclidinium | umeclidinium | Indacaterol | Review | tiotropium | Vilanterol | Formoterol | glycopyrronium | Olodaterol
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 08/2018, Volume 379, Issue 6, pp. 591 - 591
Journal Article
Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 3 - 5
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide, and it is associated with a high economic burden. Heart... 
Case Report | Heart failure | Indacaterol/glycopyrronium | Chronic obstructive pulmonary disease | UNITED-STATES | RESPIRATORY SYSTEM | ADULTS | COPD | Tiotropium | Care and treatment | Pantoprazole | Lung diseases | Cardiac patients | Mortality | Apixaban | Indacaterol
Journal Article
Respiratory Research, ISSN 1465-9921, 07/2017, Volume 18, Issue 1, pp. 140 - 9
Background: Dual bronchodilation combining a long-acting beta(2)-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) is the preferred choice of... 
Indacaterol/glycopyrronium | Open-label | Chronic obstructive pulmonary disease | Dual bronchodilation | Direct switch | INDACATEROL | MULTICENTER | QVA149 | SALMETEROL-FLUTICASONE | SALMETEROL/FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | DOUBLE-BLIND | EXACERBATIONS | TIOTROPIUM | GLYCOPYRRONIUM | Indans - adverse effects | Prospective Studies | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Patient Safety | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Dyspnea - diagnosis | Europe | Risk Factors | Treatment Outcome | Dyspnea - physiopathology | Lung - physiopathology | Disease Progression | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Dyspnea - drug therapy | Aged | Drug Substitution | Health Status | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Corticosteroids | Patient outcomes | Dosage and administration | Indacaterol | Drug therapy, Combination | Research | Drug therapy | Performance evaluation | Bronchodilation | Drugs | Medical research | Gold | Respiratory function | Acetylcholine receptors (muscarinic) | Control methods | Lung diseases | Clinical trials | Disease control | Patients | Primary care | Randomization | Dyspnea | Motivation | Obstructive lung disease | Clinical medicine | Safety | Respiration | glycopyrronium
Journal Article
Respiration, ISSN 0025-7931, 04/2018, Volume 95, Issue Suppl 1, pp. 19 - 21
Chronic obstructive pulmonary disease is a highly prevalent disease, especially in the aging population, associated with several functional disabilities and a... 
Case Report | Indacaterol/glycopyrronium | Severe respiratory failure | Chronic obstructive pulmonary disease | INDACATEROL | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | LUNG HYPERINFLATION | COPD | Tiotropium | Lung diseases, Obstructive | Indacaterol | Respiratory insufficiency | Drug therapy
Journal Article
Multidisciplinary respiratory medicine, ISSN 2049-6958, 2014, Volume 9, Issue 1, pp. 50 - 50
The most recent guidelines define COPD in a multidimensional way, nevertheless the diagnosis is still linked to the limitation of airflow, usually measured by... 
Bronchodilation | Fixed combination indacaterol/glycopyrronium | Dyspnea | Hyperinflation | LABA | HRQoL | Exercise tolerance | LAMA | COPD | RESPIRATORY SYSTEM | Development and progression | Respiratory agents | Lung diseases, Obstructive | Care and treatment
Journal Article
International journal of chronic obstructive pulmonary disease, ISSN 1178-2005, 2019, Volume 14, pp. 249 - 260
Purpose: In contrast to randomized controlled trials (RCTs), changes in maintenance pharmacotherapy in clinical practice occur without a washout period. The... 
Indacaterol/glycopyrronium | Dyspnea | Lung function | COPD assessment test | FEV | TDI | FEV1 | VILANTEROL | INHALED CORTICOSTEROIDS | QVA149 | RISK | dyspnea | SALMETEROL-FLUTICASONE | OBSTRUCTIVE PULMONARY-DISEASE | lung function | RESPIRATORY SYSTEM | DUAL BRONCHODILATION | DOUBLE-BLIND | EXACERBATIONS | TRIPLE THERAPY | indacaterol/glycopyrronium | Salmeterol/fluticasone | Tiotropium
Journal Article
Respiratory Research, ISSN 1465-9921, 06/2018, Volume 19, Issue 1, pp. 121 - 8
Journal Article